Unicycive Therapeutics, Inc. Income Statement
UNCY|3 years of annual SEC 10-K data (FY2022-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Unicycive Therapeutics, Inc. reported $675,000 in revenue and $31M in net loss for FY2024. Revenue has declined at a 15.8% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $675.0K | $951.0K | $951.0K |
| SG&A Expense | $8.5M | $6.6M | $245.0K |
| R&D Expense | $12.9M | $12.4M | $6.1M |
| Operating Income | -$20.8M | -$18.1M | -$9.0M |
| Interest Expense | - | $6.0K | $628.0K |
| Net Income | -$30.5M | -$18.1M | -$10.0M |
| EPS (Basic) | -$1.28 | -$1.20 | -$0.86 |
| EPS (Diluted) | -$1.28 | -$1.20 | -$0.86 |
| Shares Outstanding | 34.8M | 15.2M | 15.0M |
| Operating Margin | -3077.6% | -1898.2% | -944.0% |
| Profit Margin | -4525.0% | -1898.8% | -1053.3% |